Cancer Database Query Results

Scientific Papers found: Click to Expand⟱
7722- IP6,    Cancer inhibition by inositol hexaphosphate (IP6) and inositol: from laboratory to clinic
- Review, Var, NA
eff↑, TumCP↓, Diff↑, TumCCA↑, Imm↑, antiOx↑, BioAv↑, toxicity↓, ChemoSen↑, TumMeta↓, QoL↑,
7723- IP6,    Prostate cancer and inositol hexaphosphate: efficacy and mechanisms
- Review, Pca, NA
toxicity↓, AntiCan↑, TumCG↓, TumCCA↑, angioG↓,
7724- IP6,    Inositol hexakisphosphate blocks tumor cell growth by activating apoptotic machinery as well as by inhibiting the Akt/NFkappaB-mediated cell survival pathway
- in-vitro, Cerv, HeLa
NF-kB↓, Akt↓, MMP↓, Cyt‑c↑, Apoptosis↑, Casp3↑, Casp9↑, PARP↑, eff↑,
7729- IP6,    Influence of concomitant food intake on the excretion of orally administered myo-inositol hexaphosphate in humans
- Human, Nor, NA
*BioAv↝,
7728- IP6,    G0/G1 arrest and S phase inhibition of human cancer cell lines by inositol hexaphosphate (IP6)
- in-vitro, BC, MCF7 - in-vitro, BC, MDA-MB-231 - in-vitro, CRC, HT-29
AntiCan↑, TumCCA↑, Ki-67↓, PCNA↓,
7725- IP6,    Inositol hexaphosphate inhibits growth and induces differentiation of PC-3 human prostate cancer cells
- in-vitro, Pca, PC3
TumCG↓, HLA-I/II↑, Diff↑,
7726- IP6,    Inositol hexaphosphate (IP6) blocks proliferation of human breast cancer cells through a PKCdelta-dependent increase in p27Kip1 and decrease in retinoblastoma protein (pRb) phosphorylation
- in-vitro, BC, MCF7
AntiCan↑, PKCδ↑, ERK↓, Akt↓, p27/CDKN1B↑, p‑pRB↓,
7727- IP6,    Suppression of colonic cancer by dietary phytic acid
- Review, Nor, NA
*IronCh↑, *ROS↓, Risk↓,
7695- IP6,    The effect of inositol hexaphosphate on the expression of selected metalloproteinases and their tissue inhibitors in IL-1β-stimulated colon cancer cells
- in-vitro, Colon, Caco-2
AntiCan↑, TumCA↓, TumCMig↓, MMP13↓, MMP3↓, MMP2↓, TIMP1↓, MMP1↓, MMP9↓, TIMP2↓,
7640- IP6,  Ins,    Effects of Inositol Hexaphosphate and Myo-Inositol Administration in Breast Cancer Patients during Adjuvant Chemotherapy
- Trial, BC, NA
*antiOx↑, QoL↑, RBC↑, HemoG↑, WBC↑, chemoP↑, Dose↝,
7642- IP6,    Inositol Hexaphosphate Inhibits Proliferation and Induces Apoptosis of Colon Cancer Cells by Suppressing the AKT/mTOR Signaling Pathway
- in-vitro, CRC, NA
AntiCan↑, TumCP↓, Apoptosis↑, P21↑, p27/CDKN1B↑, Casp3↑, Casp9↑, AKT1↓, S6K↓, mTOR↓,
7644- IP6,  MS-275,    Apoptotic effect of IP6 was not enhanced by co-treatment with myo-inositol in prostate carcinoma PC3 cells
- in-vitro, Pca, PC3
Casp3↑, eff∅,
7645- IP6,  Ins,    Anticancer Properties of Inositol Hexaphosphate and Inositol: An Overview
AntiCan↑, TumCP↓, Apoptosis↑, Diff↑, p27/CDKN1B↓, pRB↓, PI3K↓, RAS↓, ERK↓, Akt↓, NF-kB↓, Inflam↓, AntiTum↓,
7646- IP6,  Ins,    Protection against cancer by dietary IP6 and inositol
- Review, Var, NA
*antiOx↑, TumCG↓, TumMeta↓, Imm↑, kidSt↓, LDL↓, TumCCA↑, TumCP↓, Diff↑, ChemoSen↑, QoL↑,
7690- IP6,  Ins,    Inositol Hexaphosphate (IP6) and Colon Cancer: From Concepts and First Experiments to Clinical Application
- Review, Colon, NA
AntiCan↑, Imm↑, antiOx↑, TumCP↓, Diff↑, TumCG↓, eff↑, P21↓, p27/CDKN1B↓, pRB↓, TumCCA↑, PI3K↓, Akt↓, PKCδ↓, RAS↓, ERK↓, NF-kB↓, Inflam↓, MMP9↓, IronCh↑, NK cell↑, selectivity↑, ChemoSen↑, chemoP↑, toxicity↓, Remission↑,
7691- IP6,    Inositol Hexaphosphate Suppresses Growth and Induces Apoptosis in Prostate Carcinoma Cells in Culture and Nude Mouse Xenograft: PI3K-Akt Pathway as Potential Target
- vitro+vivo, Pca, PC3 - in-vitro, Pca, C4-2B
TumCP↓, Apoptosis↑, Casp3↑, cl‑PARP↑, Akt↓, PI3K↓, p‑GSK‐3β↓, cycD1/CCND1↓, TumVol↓, TumW↓, PCNA↓, angioG↓, CD31/PECAM-1↓, ILK↓, VEGF↓, eNOS↓, Hif1a↓,
7692- IP6,    Inositol hexaphosphate inhibits constitutive activation of NF- kappa B in androgen-independent human prostate carcinoma DU145 cells
- in-vitro, Pca, DU145
NF-kB↓, IκB↑, TumCG↓,
7693- IP6,    Inositol hexaphosphate (IP6) inhibits key events of cancer metastasis: I. In vitro studies of adhesion, migration and invasion of MDA-MB 231 human breast cancer cells
- in-vitro, BC, MDA-MB-231
TumCA↓, MMP9↓,
7694- IP6,    Inositol hexaphosphate (IP6) inhibits key events of cancer metastasis: II. Effects on integrins and focal adhesions
- in-vitro, BC, MDA-MB-231
ITGA5↓, ITGB3↓,
7696- IP6,  Ins,    The Combination of Inositol Hexaphosphate and Inositol Inhibits Metastasis of Colorectal Cancer Cells by Upregulating Claudin 7
- vitro+vivo, Colon, SW48 - in-vitro, Colon, SW-620
AntiCan↑, CLDN7↑, EMT↓, E-cadherin↑, N-cadherin↓, eff↑, TumCG↓,
7698- IP6,    Dietary Phytic Acid, Dephytinization, and Phytase Supplementation Alter Trace Element Bioavailability-A Narrative Review of Human Interventions
- Review, Nor, NA
*Iron↓, *Zn2+↓, *other↝, *IronCh↑,
7699- IP6,    IP6: From Seeds to Science—A Natural Compound’s Path to Clinical Promise
- Review, Var, NA
*Iron∅, ChemoSen↑, *cardioP↑, neuroP↑, IronCh∅, P21↓, p27/CDKN1B↓, p‑pRB↓, PI3K↓, Akt↓, NF-kB↓, Inflam↓, TumW↓, TumCI↓, TumMeta↓, Imm↑, Diff↑, selectivity↑, toxicity↓, RenoP↑, QoL↑,
7700- IP6,    A84 THE USE OF PHYTASE TO ENHANCE DIETARY IRON AND ZINC ABSORPTION - A SCOPING REVIEW
- Review, Nor, NA
*Iron↓, *eff↑,
7701- IP6,    Inositol hexaphosphate sensitizes hepatocellular carcinoma to oxaliplatin relating inhibition of CCN2-LRP6-β-catenin-ABCG1 signaling pathway
- vitro+vivo, HCC, Hep3B - NA, NA, MHCC-97H
AntiCan↑, ChemoSen↑, LRP6↓, Wnt↓, β-catenin/ZEB1↓, CCN2/CTGF↓, ABCG1↓, TumCP↓, TumCMig↓,
7702- IP6,  Ins,  capec,    Inositol Hexakisphosphate and Inositol Enhance the Inhibition of Colorectal Cancer Growth and Liver Metastasis by Capecitabine in a Mouse Model
- in-vivo, CRC, NA
Dose↝, AntiTum↑, OS↑, TumW↓, TumMeta↓, E-cadherin↑, N-cadherin↓, Vim↓, TNF-α↓, IL6↓, IL8↓, ChemoSen↑,
7704- IP6,    Inositol hexaphosphate hydrolysate competitively binds to AKT to inhibit the proliferation of colon carcinoma
- in-vitro, CRC, SW-620
TumCG↓, Akt↓, other↝,
7705- IP6,    Inositol hexaphosphate (InsP6) as an effective topical treatment for patients receiving adjuvant chemotherapy after breast surgery

1088- IP6,    Preventive Inositol Hexaphosphate Extracted from Rice Bran Inhibits Colorectal Cancer through Involvement of Wnt/β-Catenin and COX-2 Pathways
- in-vivo, CRC, NA
AntiTum↑, β-catenin/ZEB1↓, COX2/PTGS2↓,
1293- IP6,    Inositol Hexaphosphate Inhibits Growth and Induces G1 Arrest and Apoptotic Death of Androgen-Dependent Human Prostate Carcinoma LNCaP Cells
- vitro+vivo, Pca, LNCaP
TumCG↓, TumCCA↑, P21↑, CDK4↓, cycD1/CCND1↓, RB1↑, E2Fs↓,
7743- ISL,    Pharmacokinetics, biodistribution and bioavailability of isoliquiritigenin after intravenous and oral administration
- in-vivo, Nor, NA
*Dose↝, *Half-Life↝, *BioAv↝, *BioAv↝,
7744- ISL,    Isoliquiritigenin suppresses fatty acid synthesis and cancer cell migration in anaplastic thyroid carcinoma through AMPK/SREBF1 pathway
- vitro+vivo, Thyroid, NA
AntiTum↑, TumCP↓, TumCMig↓, E-cadherin↑, N-cadherin↓, FASN↓, SREBP1/SREBF1↓, ATP↓, p‑AMPK↑, lipidLev↓, TumCG↓, lipoGen↓,
7753- ISL,  LE,    Pharmacokinetic Interactions of a Licorice Dietary Supplement with Cytochrome P450 Enzymes in Female Participants
- in-vivo, Nor, NA
*Dose↝,
7751- ISL,  LE,    Cytochrome P450 inhibition by three licorice species and fourteen licorice constituents
*CYP2C6↓, *CYP3A4↓, *P450↓, *other↑,
7752- ISL,    Isoliquiritigenin showed strong inhibitory effects towards multiple UDP-glucuronosyltransferase (UGT) isoform-catalyzed 4-methylumbelliferone (4-MU) glucuronidation
- in-vitro, Nor, NA
*UGT1A↓,
7763- ISL,    Harnessing Liquiritigenin: A Flavonoid-Based Approach for the Prevention and Treatment of Cancer
AntiCan↑, *antiOx↓, *Inflam↓, TumCP↓, Apoptosis↑, NF-kB↓, PI3K↓, Akt↓, mTOR↓, *AntiArt↑, Casp8↑, Cyt‑c↑, Casp↑, cl‑PARP↑, GutMicro↑, BioAv↑, BioAv↓, Half-Life↓,
7745- ISL,    Isoliquiritigenin inhibits colorectal cancer progression by targeting the FGFR4/FASN mediated lipid metabolism pathway
- in-vitro, CRC, NA
AntiCan↑, TumCP↓, TumCMig↓, FASN↓, FGFR4/CD334↓, PI3K↓, Akt↓,
7746- ISL,    Isoliquiritigenin Inhibits the Growth of Colorectal Cancer Cells through the ESR2/PI3K/AKT Signalling Pathway
- vitro+vivo, CRC, SW480 - vitro+vivo, CRC, HCT116
AntiCan↑, tumCV↓, Apoptosis↑, TumCCA↑, TumCG↓, PI3K↓, Akt↓, p‑Akt↓, p‑GSK‐3β↓, CDK1↓, NF-kB↓, Bcl-2↓, ERβ/ESR2↑, BAX↑, Bax:Bcl2↑, ROS↑,
7747- ISL,    Isoliquiritigenin Induces Apoptosis via ROS-Mediated Inhibition of p38/mTOR/STAT3 Pathway in Human Melanoma Cells
- in-vitro, Melanoma, SK-MEL-28
*Inflam↓, *AntiViral↑, *AntiTum↑, *antiOx↑, cl‑Casp9↑, cl‑Casp7↑, cl‑Casp3↑, cl‑PARP↑, BAX↑, Bcl-2↓, Cyt‑c↑, cycD1/CCND1↓, cycD1/CCND1↓, survivin↓, ROS↓, eff↓, p‑mTOR↓, p‑STAT3↓, p‑MAPK↓,
7748- ISL,  GEM,    Isoliquiritigenin combined with gemcitabine inhibited lung cancer by suppressing JAK2/STAT3 signaling via lncRNA-p21/miRNA-4534 axis
- NA, Lung, NA
Dose↝, Apoptosis↑, TumCP↓, TumCI↓, TumMeta↓, P21↑, selectivity↑, JAK2↓, STAT3↓,
7749- ISL,    Inhibition of COX-2, mPGES-1 and CYP4A by isoliquiritigenin blocks the angiogenic Akt signaling in glioma through ceRNA effect of miR-194-5p and lncRNA NEAT1
- in-vitro, GBM, U87MG
angioG↓, COX2/PTGS2↓, mPGES-1↓, CYP4A/CYP4A11/CYP4A22↓, FGF21↓, TGF-β↓, VEGF↓, miR-194↑, NEAT1↓,
7750- ISL,    Isoliquiritigenin in Breast Cancer: A Systematic Review of Its Preventive and Anti-metastatic Mechanisms
- Review, BC, NA
AntiCan↑, Apoptosis↑, TumAuto↑, mTOR↓, AApath↓, EMT↓, BRCA1↝, PI3K↓, Akt↓, angioG↓, VEGF↓, Hif1a↓, COX2/PTGS2↓, NF-kB↓,
7754- ISL,    Isoliquiritigenin Confers Neuroprotection and Alleviates Amyloid-β42-Induced Neuroinflammation in Microglia by Regulating the Nrf2/NF-κB Signaling
- in-vitro, AD, BV2
*Inflam↓, *NO↓, *NRF2↑, *NF-kB↓, *neuroP↑,
7755- ISL,    Isoliquiritigenin attenuated cognitive impairment, cerebral tau phosphorylation and oxidative stress in a streptozotocin-induced mouse model of Alzheimer's disease
- in-vivo, AD, NA
*memory↑, *p‑T-cadherin↓, *ROS↓, *ATP↑, *p‑DRP1/DNM1L↝, *MFN1↝, *MFN2↝, *neuroP↑, *cognitive↑, *mTOR↓, *ERK↓, *GSK‐3β↑,
7756- ISL,    Dietary compound isoliquiritigenin inhibits breast cancer neoangiogenesis via VEGF/VEGFR-2 signaling pathway
- vitro+vivo, BC, MCF7 - vitro+vivo, BC, MDA-MB-231
AntiCan↑, VEGF↓, TumCI↓, TumCMig↓, Hif1a↓, TumCG↓, angioG↓, VEGFR2/KDR/Flk1↓, Apoptosis↑, toxicity↓, TumCCA↑, Inflam↓, ROS↑,
7757- ISL,    Isoliquiritigenin Suppresses Oral Squamous Cell Carcinoma Progression by Targeting FABP5-Mediated Lipid Metabolism: Association with the circPOLB/miR-548ae-3p/C-MYC Axis
- in-vitro, Oral, NA
FABP5/E-FABP↓, FAM↓, TumCI↓, lipidLev↓,
7758- ISL,    Targeting the JAK/STAT pathway with isoliquiritigenin in ovarian cancer: molecular mechanisms and therapeutic implications
- Review, Ovarian, NA
JAK↓, STAT↓, toxicity↓, *antiOx↑, *ROS↓, *NRF2↑, *ARE↑, *HO-1↑, *NQO1↑, *Inflam↓, *NF-kB↓, *MAPK↓, *SOD↑, *Catalase↑, *GPx↑, *AntiViral↑, *NADPH↑, ROS↓, p38↓, mTOR↓, STAT3↓, cycD1/CCND1↓, survivin↓, p38↑, MAPK↑, mtDam↑, ER Stress↑, ROS↑, Apoptosis↑, GLUT4↓, ATP↓, Glycolysis↓, eff↑,
7759- ISL,  Rad,    Isoliquiritigenin, a Bioactive Blood Component Derived from Licorice, Activates Nrf2 Enzymes to Confer Protection Against Radiation-Induced Nerve Injury
- vitro+vivo, Nor, PC12
*radioP↑, *LDH↓, *ROS↓, *SOD1↑, *GSH↑, *TAC↑, *NRF2↓, *cognitive↑, *Learn↑, *memory↑,
7760- ISL,    Pharmacological Potentials and Delivery Strategies of Isoliquiritigenin: Challenges and Advances in Enhancing Bioavailability
- Review, Nor, NA
*BioAv↓, GlucoseCon↓, LDH↓, PDK1 / PDPK1↓, Glycolysis↓, mt-OXPHOS↓, Bax:Bcl2↓, cl‑Casp3↑, cl‑Casp9↑, Apoptosis↑, Hif1a↓, ROS↑, *AntiDiabetic↑, *cardioP↑, *RenoP↑, *ROS↓, *NF-kB↓, *NLRP3↓, *Pyro↓, *antiPs↑, *IL6↓, *IL8↓, BioAv↑, BioAv↑, BioAv↑,
7761- ISL,    Targeting digestive system cancers with isoliquiritigenin: a comprehensive review of antitumor mechanisms
- Review, Var, NA
Apoptosis↑, TumAuto↑, TumCCA↑, ROS↑, JNK↑, p38↑, STAT3↑, NF-kB↓, IκB↑, Bcl-2↓, BAX↑, cl‑Casp3↑, cl‑PARP↑, P21↑, p27/CDKN1B↑, CycB/CCNB1↑, CDK1↓, CDK2↓, GRP78/BiP↓, PI3K↓, Akt↓, mTOR↓, eff↑, GLUT4↓, lactateProd↓, OXPHOS↓, Glycolysis↓, BioAv↑, ENO1↓, ALDOA↓, LDHA↓, MCT4↓, RadioS↑, Ferroptosis↑, i-Iron↑, BioAv↑, Half-Life↓,
7762- ISL,    Isoliquiritigenin reduces brain metastasis by circNAV3-ST6GALNAC5-EGFR axis in triple-negative breast cancer
- in-vivo, BC, NA
TumMeta↓, circNAV3↓,

Showing Research Papers: 4951 to 5000 of 8269
Prev Page 100 of 166 Next

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 8269

Pathway results for Effect on Cancer / Diseased Cells:


NA, unassigned(tgid=0) ⓘ

AApath↓, 1,   ABCG1↓, 1,   circNAV3↓, 1,   CLDN7↑, 1,   CYP4A/CYP4A11/CYP4A22↓, 1,   FABP5/E-FABP↓, 1,   FAM↓, 1,   FGFR4/CD334↓, 1,   HLA-I/II↑, 1,   ILK↓, 1,   kidSt↓, 1,   NEAT1↓, 1,   RBC↑, 1,   WBC↑, 1,  

Redox & Oxidative Stress(tgid=1) ⓘ

antiOx↑, 2,   Ferroptosis↑, 1,   i-Iron↑, 1,   OXPHOS↓, 1,   mt-OXPHOS↓, 1,   ROS↓, 2,   ROS↑, 5,  

Metal & Cofactor Biology(tgid=2) ⓘ

IronCh↑, 1,   IronCh∅, 1,  

Mitochondria & Bioenergetics(tgid=3) ⓘ

ATP↓, 2,   MMP↓, 1,   mtDam↑, 1,  

Core Metabolism/Glycolysis(tgid=4) ⓘ

AKT1↓, 1,   ALDOA↓, 1,   p‑AMPK↑, 1,   ENO1↓, 1,   FASN↓, 2,   FGF21↓, 1,   GlucoseCon↓, 1,   Glycolysis↓, 3,   lactateProd↓, 1,   LDH↓, 1,   LDHA↓, 1,   LDL↓, 1,   lipidLev↓, 2,   lipoGen↓, 1,   MCT4↓, 1,   PDK1 / PDPK1↓, 1,   S6K↓, 1,   SREBP1/SREBF1↓, 1,  

Cell Death(tgid=5) ⓘ

Akt↓, 12,   p‑Akt↓, 1,   Apoptosis↑, 12,   BAX↑, 3,   Bax:Bcl2↓, 1,   Bax:Bcl2↑, 1,   Bcl-2↓, 3,   Casp↑, 1,   Casp3↑, 4,   cl‑Casp3↑, 3,   cl‑Casp7↑, 1,   Casp8↑, 1,   Casp9↑, 2,   cl‑Casp9↑, 2,   Cyt‑c↑, 3,   Ferroptosis↑, 1,   JNK↑, 1,   MAPK↑, 1,   p‑MAPK↓, 1,   p27/CDKN1B↓, 3,   p27/CDKN1B↑, 3,   p38↓, 1,   p38↑, 2,   survivin↓, 2,  

Transcription & Epigenetics(tgid=7) ⓘ

other↝, 1,   pRB↓, 2,   p‑pRB↓, 2,   tumCV↓, 1,  

Protein Folding & ER Stress(tgid=8) ⓘ

ER Stress↑, 1,   GRP78/BiP↓, 1,  

Autophagy & Lysosomes(tgid=9) ⓘ

TumAuto↑, 2,  

DNA Damage & Repair(tgid=10) ⓘ

BRCA1↝, 1,   PARP↑, 1,   cl‑PARP↑, 4,   PCNA↓, 2,  

Cell Cycle & Senescence(tgid=11) ⓘ

CDK1↓, 2,   CDK2↓, 1,   CDK4↓, 1,   CycB/CCNB1↑, 1,   cycD1/CCND1↓, 5,   E2Fs↓, 1,   P21↓, 2,   P21↑, 4,   RB1↑, 1,   TumCCA↑, 9,  

Proliferation, Differentiation & Cell State(tgid=12) ⓘ

Diff↑, 6,   EMT↓, 2,   ERK↓, 3,   p‑GSK‐3β↓, 2,   LRP6↓, 1,   miR-194↑, 1,   mTOR↓, 5,   p‑mTOR↓, 1,   PI3K↓, 9,   RAS↓, 2,   STAT↓, 1,   STAT3↓, 2,   STAT3↑, 1,   p‑STAT3↓, 1,   TumCG↓, 11,   Wnt↓, 1,  

Migration(tgid=13) ⓘ

CCN2/CTGF↓, 1,   CD31/PECAM-1↓, 1,   E-cadherin↑, 3,   ITGA5↓, 1,   ITGB3↓, 1,   Ki-67↓, 1,   MMP1↓, 1,   MMP13↓, 1,   MMP2↓, 1,   MMP3↓, 1,   MMP9↓, 3,   N-cadherin↓, 3,   PKCδ↓, 1,   PKCδ↑, 1,   TGF-β↓, 1,   TIMP1↓, 1,   TIMP2↓, 1,   TumCA↓, 2,   TumCI↓, 4,   TumCMig↓, 5,   TumCP↓, 11,   TumMeta↓, 6,   Vim↓, 1,   β-catenin/ZEB1↓, 2,  

Angiogenesis & Vasculature(tgid=14) ⓘ

angioG↓, 5,   eNOS↓, 1,   Hif1a↓, 4,   VEGF↓, 4,   VEGFR2/KDR/Flk1↓, 1,  

Barriers & Transport(tgid=15) ⓘ

GLUT4↓, 2,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

COX2/PTGS2↓, 3,   IL6↓, 1,   IL8↓, 1,   Imm↑, 4,   Inflam↓, 4,   IκB↑, 2,   JAK↓, 1,   JAK2↓, 1,   mPGES-1↓, 1,   NF-kB↓, 9,   NK cell↑, 1,   TNF-α↓, 1,  

Hormonal & Nuclear Receptors(tgid=20) ⓘ

ERβ/ESR2↑, 1,  

Drug Metabolism & Resistance(tgid=21) ⓘ

BioAv↓, 1,   BioAv↑, 7,   ChemoSen↑, 6,   Dose↝, 3,   eff↓, 1,   eff↑, 6,   eff∅, 1,   Half-Life↓, 2,   RadioS↑, 1,   selectivity↑, 3,  

Clinical Biomarkers(tgid=22) ⓘ

BRCA1↝, 1,   GutMicro↑, 1,   HemoG↑, 1,   IL6↓, 1,   Ki-67↓, 1,   LDH↓, 1,  

Functional Outcomes(tgid=23) ⓘ

AntiCan↑, 14,   AntiTum↓, 1,   AntiTum↑, 3,   chemoP↑, 2,   neuroP↑, 1,   OS↑, 1,   QoL↑, 4,   Remission↑, 1,   RenoP↑, 1,   Risk↓, 1,   toxicity↓, 6,   TumVol↓, 1,   TumW↓, 3,  
Total Targets: 177

Pathway results for Effect on Normal Cells:


NA, unassigned(tgid=0) ⓘ

AntiArt↑, 1,   Learn↑, 1,   UGT1A↓, 1,  

Redox & Oxidative Stress(tgid=1) ⓘ

antiOx↓, 1,   antiOx↑, 4,   ARE↑, 1,   Catalase↑, 1,   GPx↑, 1,   GSH↑, 1,   HO-1↑, 1,   Iron↓, 2,   Iron∅, 1,   MFN1↝, 1,   MFN2↝, 1,   NQO1↑, 1,   NRF2↓, 1,   NRF2↑, 2,   ROS↓, 5,   SOD↑, 1,   SOD1↑, 1,   TAC↑, 1,  

Metal & Cofactor Biology(tgid=2) ⓘ

IronCh↑, 2,   Zn2+↓, 1,  

Mitochondria & Bioenergetics(tgid=3) ⓘ

ATP↑, 1,   p‑DRP1/DNM1L↝, 1,  

Core Metabolism/Glycolysis(tgid=4) ⓘ

CYP2C6↓, 1,   CYP3A4↓, 1,   LDH↓, 1,   NADPH↑, 1,  

Cell Death(tgid=5) ⓘ

MAPK↓, 1,   Pyro↓, 1,  

Transcription & Epigenetics(tgid=7) ⓘ

other↑, 1,   other↝, 1,  

Proliferation, Differentiation & Cell State(tgid=12) ⓘ

ERK↓, 1,   GSK‐3β↑, 1,   mTOR↓, 1,   Zn2+↓, 1,  

Migration(tgid=13) ⓘ

p‑T-cadherin↓, 1,  

Angiogenesis & Vasculature(tgid=14) ⓘ

NO↓, 1,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

IL6↓, 1,   IL8↓, 1,   Inflam↓, 4,   NF-kB↓, 3,  

Protein Aggregation(tgid=19) ⓘ

NLRP3↓, 1,  

Drug Metabolism & Resistance(tgid=21) ⓘ

BioAv↓, 1,   BioAv↝, 3,   Dose↝, 2,   eff↑, 1,   Half-Life↝, 1,   P450↓, 1,  

Clinical Biomarkers(tgid=22) ⓘ

IL6↓, 1,   LDH↓, 1,  

Functional Outcomes(tgid=23) ⓘ

AntiDiabetic↑, 1,   antiPs↑, 1,   AntiTum↑, 1,   cardioP↑, 2,   cognitive↑, 2,   memory↑, 2,   neuroP↑, 2,   radioP↑, 1,   RenoP↑, 1,  

Infection & Microbiome(tgid=24) ⓘ

AntiViral↑, 2,  
Total Targets: 62

Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:%  Target#:%  State#:%  Dir#:%
  wNotes=0  sortOrder:rid,rpid

 

Home Page